{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:48:07Z","timestamp":1792050487292,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.leukres.2012.01.021","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T15:18:00Z","timestamp":1330010280000},"page":"817-825","source":"Crossref","is-referenced-by-count":49,"title":["Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia"],"prefix":"10.1016","volume":"36","author":[{"given":"Adam","family":"Gater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Abetz-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.leukres.2012.01.021_bib0005","first-page":"S1","article-title":"NCCN task force report: oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"JNCCN: J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.leukres.2012.01.021_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11912-010-0103-6","article-title":"Oral cancer chemotherapy: the critical interplay between patient education and patient safety","volume":"12","author":"Halfdanarson","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"February (3)","key":"10.1016\/j.leukres.2012.01.021_bib0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"issue":"May (9)","key":"10.1016\/j.leukres.2012.01.021_bib0025","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2012.01.021_bib0030","series-title":"Adherence to oral cancer therapies: meeting the challenge of new patient care needs. Special report","author":"Blasdel","year":"2006"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.leukres.2012.01.021_bib0040","unstructured":"Sabate E. Adherence to long-term therapies: evidence for action (WHO); 2003 [PM:14562485]."},{"issue":"March (3)","key":"10.1016\/j.leukres.2012.01.021_bib0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients\u2019 adherence to medical recommendations: a quantitative review of 50 years of research","volume":"42","author":"Dimatteo","year":"2004","journal-title":"Med Care"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JOP.2010.000076","article-title":"Perspectives on adherence and persistence with oral medications for cancer treatment","volume":"7","author":"Hohneker","year":"2011","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.leukres.2012.01.021_bib0055","series-title":"Gleevec [package insert]","year":"2009"},{"key":"10.1016\/j.leukres.2012.01.021_bib0060","unstructured":"US Food and Drug Administration. Gleevec (imatinib mesylate), <http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm110502.htm>; 2001."},{"key":"10.1016\/j.leukres.2012.01.021_bib0065","series-title":"Harrison's principles of internal medicine","first-page":"631","article-title":"Acute and chronic myeloid leukemia","author":"Wetzler","year":"2005"},{"key":"10.1016\/j.leukres.2012.01.021_bib0070","first-page":"1126","article-title":"International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (23)","key":"10.1016\/j.leukres.2012.01.021_bib0075","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"issue":"June (11)","key":"10.1016\/j.leukres.2012.01.021_bib0085","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","article-title":"Current and emerging treatment options in chronic myeloid leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.01.021_bib0090","series-title":"Tasigna [package insert]","year":"2009"},{"key":"10.1016\/j.leukres.2012.01.021_bib0095","series-title":"Sprycel [package insert]","year":"2009"},{"issue":"December (35)","key":"10.1016\/j.leukres.2012.01.021_bib0100","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"June (24)","key":"10.1016\/j.leukres.2012.01.021_bib0105","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"November (10)","key":"10.1016\/j.leukres.2012.01.021_bib0110","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.01.021_bib0115","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"September (9)","key":"10.1016\/j.leukres.2012.01.021_bib0120","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia [Review]","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.01.021_bib0125","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukaemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"January (2)","key":"10.1016\/j.leukres.2012.01.021_bib0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2010.10.018","article-title":"Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? [Review]","volume":"300","author":"Breccia","year":"2011","journal-title":"Cancer Lett"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.leukres.2012.01.021_bib0140","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"22","key":"10.1016\/j.leukres.2012.01.021_bib0145","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"May (14)","key":"10.1016\/j.leukres.2012.01.021_bib0150","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.leukres.2012.01.021_bib0155","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.leukres.2008.04.018","article-title":"Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase","volume":"33","author":"Kiguchi","year":"2009","journal-title":"Leuk Res"},{"issue":"May (5)","key":"10.1016\/j.leukres.2012.01.021_bib0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.leukres.2012.01.021_bib0165","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"June (6)","key":"10.1016\/j.leukres.2012.01.021_bib0170","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2012.01.021_bib0175","first-page":"S1","article-title":"The variance in patient reported non adherence with imatinib treatment in chronic myeloid leukemia is attributable to both physicians and patients \u2013 results from the ADAGIO study","volume":"93","author":"Abraham","year":"2008","journal-title":"Haematologica"},{"issue":"December (21)","key":"10.1016\/j.leukres.2012.01.021_bib0180","first-page":"4477","article-title":"High adherence to tyrosine kinase inhibitors seems to be related to best cytogenetic response in the Hasford lower risk group in chronic myeloid leukemia","volume":"116","author":"Almeida","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2012.01.021_bib0185","first-page":"343","article-title":"Adherence to tyrosine kinase inhibitors (TK1) in chronic myeloid leukemia (CML) seems to be related to duration of treatment and type of TK1","volume":"95","author":"Almeida","year":"2010","journal-title":"Haematologica"},{"issue":"December (22)","key":"10.1016\/j.leukres.2012.01.021_bib0190","first-page":"3290","article-title":"Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients","volume":"114","author":"Bazeos","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (11)","key":"10.1016\/j.leukres.2012.01.021_bib0195","first-page":"4267","article-title":"Adherence to imatinib mesylate treatment: two years follow up","volume":"112","author":"Doti","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"18S (June Suppl.)","key":"10.1016\/j.leukres.2012.01.021_bib0200","article-title":"Compliance and persistency with imatinib","volume":"24","author":"Feng","year":"2006","journal-title":"J Clin Oncol"},{"issue":"December (21)","key":"10.1016\/j.leukres.2012.01.021_bib0205","first-page":"2296","article-title":"Impact of comorbidity in event-free survival, toxicity and adherence to treatment in chronic myeloid leukemia patients treated with imatinib","volume":"116","author":"Fogliatto","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (21)","key":"10.1016\/j.leukres.2012.01.021_bib0210","first-page":"3437","article-title":"Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia","volume":"116","author":"Guerin","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"20 (May Suppl.)","key":"10.1016\/j.leukres.2012.01.021_bib0215","article-title":"Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate","volume":"26","author":"Halpern","year":"2008","journal-title":"J Clin Oncol"},{"issue":"December (11)","key":"10.1016\/j.leukres.2012.01.021_bib0220","first-page":"5159","article-title":"Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST","volume":"110","author":"Halpern","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (21)","key":"10.1016\/j.leukres.2012.01.021_bib0225","first-page":"3414","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term imatinib therapy","volume":"116","author":"Ibrahim","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (21)","key":"10.1016\/j.leukres.2012.01.021_bib0230","first-page":"4481","article-title":"Disease knowledge in chronic myeloid leukemia (CML) patients as a predictor of compliance to treatment","volume":"116","author":"Johnson","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (11)","key":"10.1016\/j.leukres.2012.01.021_bib0235","first-page":"2379","article-title":"Patient nonadherence and treatment response to imatinib in patients with chronic myeloid leukemia: results from the ADAGIO study","volume":"112","author":"Noens","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"December (22)","key":"10.1016\/j.leukres.2012.01.021_bib0240","first-page":"2209","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia","volume":"114","author":"St Charles","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"18S (June Suppl.)","key":"10.1016\/j.leukres.2012.01.021_bib0245","article-title":"Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM)","volume":"24","author":"Tsang","year":"2006","journal-title":"J Clin Oncol"},{"issue":"December (11)","key":"10.1016\/j.leukres.2012.01.021_bib0250","first-page":"5164","article-title":"Canonical correlation analysis (CCA) of imatinib treatment (ImRx) nonadherence (NA) with associated patient variables (APVs) in chronic myeloid leukemia (CML) \u2013 results from the ADAGIO study","volume":"110","author":"van Lierde","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.leukres.2012.01.021_bib0255","first-page":"5163","article-title":"Multimethod clinical assessment of patterns and prevalence of nonadherence to imatinib treatment in patients with chronic myeloid leukemia: results from the ADAGIO study","volume":"110","author":"van Lierde","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"18S (June Suppl.)","key":"10.1016\/j.leukres.2012.01.021_bib0260","article-title":"Medical costs associated with imatinib (IM) non-compliance in chronic myeloid leukemia (CML) patients (pts)","volume":"25","author":"Wu","year":"2007","journal-title":"J Clin Oncol"},{"issue":"December (22)","key":"10.1016\/j.leukres.2012.01.021_bib0265","first-page":"4270","article-title":"Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs","volume":"114","author":"Wu","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1016\/j.leukres.2012.01.021_bib0270","first-page":"1235","article-title":"Adherence to treatment in patients with chronic myelogenous leukemia during a 10-year time period: a medical record review","volume":"116","author":"Yood","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.leukres.2012.01.021_bib0275","unstructured":"Novartis Pharmaceuticals. Imatinib (Gleevec) prescribing information; 2011."},{"issue":"4","key":"10.1016\/j.leukres.2012.01.021_bib0280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminhematol.2010.06.003","article-title":"Current status of imatinib as frontline therapy for chronic myeloid leukemia","volume":"47","author":"Marin","year":"2010","journal-title":"Semin Hematol"},{"issue":"September (6)","key":"10.1016\/j.leukres.2012.01.021_bib0285","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.01.021_bib0290","series-title":"Management of the worker","author":"Roethlisberger","year":"1939"},{"key":"10.1016\/j.leukres.2012.01.021_bib0295","series-title":"Adherence to long term therapies: evidence for action","author":"World Health Organization","year":"2003"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0300","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"April (4286)","key":"10.1016\/j.leukres.2012.01.021_bib0305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1126\/science.847460","article-title":"The need for a new medical model: a challenge for biomedicine","volume":"196","author":"Engel","year":"1977","journal-title":"Science"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007990802619425","article-title":"The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease","volume":"25","author":"McHorney","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"January (1)","key":"10.1016\/j.leukres.2012.01.021_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1525-1497.2002.09004.x","article-title":"How well do clinicians estimate patients\u2019 adherence to combination antiretroviral therapy?","volume":"17","author":"Miller","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"August (8)","key":"10.1016\/j.leukres.2012.01.021_bib0320","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.leukres.2012.01.021_bib0325","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/08964280109595777","article-title":"Facilitation of patient involvement in care: development and validation of a scale","volume":"27","author":"Martin","year":"2001","journal-title":"Behav Med"},{"key":"10.1016\/j.leukres.2012.01.021_bib0330","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","article-title":"The theory of planned behavior","volume":"50","author":"Ajzen","year":"1991","journal-title":"Organ Behav Human Decis Process"},{"key":"10.1016\/j.leukres.2012.01.021_bib0335","series-title":"Social foundations of thought and action: a social cognitive theory","author":"Bandura","year":"1986"},{"issue":"December (4)","key":"10.1016\/j.leukres.2012.01.021_bib0340","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2307\/2955344","article-title":"The health belief model and prediction of dietary compliance: a field experiment","volume":"18","author":"Becker","year":"1977","journal-title":"J Health Soc Behav"},{"issue":"4","key":"10.1016\/j.leukres.2012.01.021_bib0345","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1037\/0022-3514.66.4.742","article-title":"The consideration of future consequences: weighing immediate and distant outcomes of behavior","volume":"66","author":"Strathman","year":"1994","journal-title":"J Pers Social Psychology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T22:50:19Z","timestamp":1543186219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0145212612000409"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.01.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}